Clinical Trial Update: Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. [Phase 2]

View source ↗

Summary

This document provides a Phase 2 trial update on subcutaneous low-dose recombinant human GM-CSF, used with or without whole lung lavage, for pulmonary alveolar …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Alveolar Proteinosis

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Pulmonary Alveolar Proteinosis | Phase 2 | Status: UNKNOWN